Derivation of Meaningful Change Thresholds for European Organization for Research and Treatment of Cancer QLQ-C30 and QLQ-LC13 in Patients With Small-Cell Lung Cancer
To our knowledge, this study is the first to estimate MWPC and MBGD thresholds specifically in patients with relapsed SCLC. Estimated threshold ranges are considered robust given the comprehensive considerations and triangulation of various methods and can help clinicians, researchers, and healthcare decision makers to evaluate the clinical meaningfulness to patients of changes in key SCLC scales over time.
Authors
- Kim Cocks (ORCID: https://orcid.org/0000-0003-2595-708X)
- Bellinda L. King‐Kallimanis (ORCID: https://orcid.org/0000-0001-9418-9374)
- Franziska Dirnberger
- Nathan Clarke
- Jessie Wang (ORCID: https://orcid.org/0000-0002-4539-3771)
- Michael T Koller (ORCID: https://orcid.org/0000-0001-5252-6010)
- Shuang Huang (ORCID: https://orcid.org/0000-0002-9674-2249)
- Sujoy Mukherjee (ORCID: https://orcid.org/0000-0001-9783-7664)
- George Skingley
Institutions
- Amgen (United States) (US)
- University Hospital Regensburg (DE)
- Adelphi Group (United Kingdom) (GB)
- Amgen (Germany) (DE)
- LUNGevity Foundation (US)
Publication Details
- Journal
- Value in Health
- Published
- 2025-09-25
- DOI
- https://doi.org/10.1016/j.jval.2025.09.011
- Primary Topic
- Lung Cancer Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00